Acute lymphocytic leukemia (ALL) is a type of cancer that develops from immature forms of lymphocytes, a type of white blood cell in the bone marrow. Although only about 40% of ALL cases occur in adults, about 80% of deaths from ALL occur in this age group (American Cancer Society, 2015). Even with improvements in first-line therapies, about 33% of standard-risk patients and 66% of high-risk patients experience disease relapse (Gökbuget et al., 2012). Salvage chemotherapy regimens for B-precursor relapsed ALL frequently involve the use of high-dose cytarabine (Cytosar®) in combination with other agents (Gökbuget et al., 2012). For patients with disease that has failed multiple therapies, complete remission (CR) occurs in only 20%–30% of patients, with a median overall survival of 3–6 months (Topp et al., 2015). Allogeneic stem cell transplantation for individuals in remission is the only curative option for adult patients with relapsed or refractory ALL (Topp et al., 2015). Therefore, achieving a CR is a valuable step in their journey for a cure.

Blinatumomab (Blincyto®), as a single-agent therapy, is an effective new immunotherapy agent to induce remissions in refractory B-cell ALL. Blinatumomab is indicated for relapsed or refractory ALL in adults (Amgen Inc., 2014). CD19 is a surface antigen expressed in B-cell development and in more than 95% of B-precursor ALL blasts, making it a promising target for immunotherapy (Raponi et al., 2011). The drug is bispecific to both CD19 and CD3 (Topp et al., 2015). Blinatumomab simultaneously binds CD3-positive cytotoxic T cells and CD19-positive B cells, causing the T cells to induce lysis of the normal and malignant B cells (Hoffmann et al., 2005).

**Indications**

In December 2014, the U.S. Food and Drug Administration (FDA), 2014 accelerated the approval of blinatumomab for relapsed or refractory Philadelphia chromosome-negative B-cell ALL. Currently, this is the only FDA-approved indication for blinatumomab therapy.